ReviewCureus2025
Arrhythmogenic Implications of Inflammatory Bowel Disease: Its Mechanisms and Treatment Effects.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease, comprising Crohn's disease and ulcerative colitis, is increasingly recognized as a systemic condition that extends beyond the gastrointestinal tract. Growing evidence indicates a significant association between inflammatory bowel disease and cardiovascular complications, particularly cardiac arrhythmias, driven by persistent inflammation and, in some cases, medication effects. This review integrates current clinical and mechanistic insights into the link between inflammatory bowel disease and arrhythmia risk. Recent epidemiological and genetic studies consistently show an elevated incidence of atrial fibrillation, atrioventricular block, and other conduction abnormalities in affected patients, independent of traditional cardiovascular risk factors. Systemic cytokine activation, autonomic dysfunction, and structural cardiac remodeling appear to be central mediators. Drug effects vary, with aminosalicylates occasionally causing reversible myocarditis, corticosteroids producing dose and duration-related cardiovascular effects, and biologic agents generally demonstrating cardiac safety. Recognizing these associations highlights the importance of comprehensive cardiovascular assessment and inflammation control in patient care. Coordinated multidisciplinary management and long-term research are essential to refine risk prediction and improve cardiac outcomes in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.